SciNeuro Pharmaceuticals Announces $53 Million Financing to Further Advance Pipeline of Therapies for Neurodegenerative Diseases and Appointment of Chief Financial Officer

ROCKVILLE, Md., Dec. 4, 2025 /PRNewswire/ -- SciNeuro Pharmaceuticals ("SciNeuro"), a biotech company pioneering the development of novel treatments for neurodegenerative diseases, today announced the completion of a total of $53 million in equity financing, led by LAV and ARCH Venture Partners with participation from new and existing investors. Together with a $5 million non-dilutive research grant recently awarded by The Michael J. Fox Foundation for Parkinson's Research (MJFF), the proceeds will support the advancement of the company's pipeline of innovative therapeutics targeting a broad range of disease pathways including Lp-PLA2¹, beta amyloid and LRRK2² as well as the ongoing discovery of novel treatments for other CNS disorders.